about
Trop-2 is a determinant of breast cancer survivalThe insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancerPhospholipase Cgamma1 is required for metastasis development and progressionEffects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice.Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancermTrop1/Epcam knockout mice develop congenital tufting enteropathy through dysregulation of intestinal E-cadherin/β-catenin.Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunctionA unique four-hub protein cluster associates to glioblastoma progression.Prognostic relevance of LGALS3BP in human colorectal carcinoma.p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading.miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression.Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer.Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancerInhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody.An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling.Alterations of MEN1 and E-cadherin/β-catenin complex in sporadic pulmonary carcinoids.Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants.HER-2/neu mediates oncogenic transformation via altered CREB expression and function.Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy.Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study.The Trop-2 signalling network in cancer growth.Intestinal tumour chemoprevention with the antioxidant lipoic acid stimulates the growth of breast cancer.Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology.Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.Trop-1 are conserved growth stimulatory molecules that mark early stages of tumor progression.Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors.Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations.A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer.P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutationsCytoplasmic Trop-1/Ep-CAM Overexpression is Associated with a Favorable Outcome in Node-positive Breast CancerHigh expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapiesPLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes
P50
Q27333611-7ADE962A-5FF3-443E-8327-3F13DF282537Q28266005-F0E50914-6F06-4196-9CC6-58B5E8A622E9Q28303679-712E0883-9DD5-4CB1-93E2-EB18DFAA4A36Q33851275-3D2D4A3C-C755-4609-B19F-96F3701F1A33Q34284302-FB4C1573-051B-4757-9A44-D6A117A9A4F7Q34499625-A9D486FF-D294-4D35-B06B-0D9EE41A110EQ34561777-579FBE5E-14A2-4C59-9C82-3E3A9E313CE9Q35210961-638831B9-2D1E-466C-BB34-B1940C6C73A7Q35899039-7AFB4E73-78A7-4EF5-84F0-B9A03D631D0EQ36107330-A5F31FE5-97C6-404E-A0CE-471A15873473Q36293886-307EFF6A-81F0-4CEB-AECC-843B7E4B2E87Q36907068-96770075-89F2-4ABF-A37C-DBA6A8CC7DEEQ37109753-37B71B30-5473-4CCB-8885-6059BDBCFE26Q37536346-E52957C7-6A19-4236-85B3-7BBA5D75CBE4Q37595930-302BC992-7062-43FC-B0EC-B5970649C9C4Q39022501-FD4AF11E-5737-4559-B636-7D06BC73234EQ39493859-1FEF58D6-3783-43D0-87FF-3C5FD63E2481Q41786175-99CBC547-A52F-4126-8CC4-A6C53B6F291DQ42721868-A687820B-87F8-4DC9-B689-95509A3D6878Q42813724-11DE925C-EF28-4AFB-9D0F-E13DEEBB9A84Q44221566-B4B1FF7C-0746-4B8A-98D3-29736BC69400Q45186671-F7E856DD-2837-4762-95CB-A5B50A07820DQ45826058-38C66A44-92A1-44B6-901A-100A7169E8D7Q46312951-80752237-89A6-4779-96A9-983FD8853712Q46457932-5B9C3C2E-17DB-4AFE-B31D-3EA4EFAF7668Q46988402-D3C61D25-8508-4461-A6FE-30F4CEAC55BAQ48141924-9CFD61CD-62C8-4462-8C18-6201F15231D1Q53135288-C6423D91-4B32-41CE-8E09-6F0715157252Q53327718-BEC3E131-862B-4559-978C-43A4EAB43A19Q53450201-61C49495-255D-4C6E-9CE3-796C1816A532Q57157305-761AA71D-15EE-49CC-8940-9F56B43011B5Q61851588-B32A645E-85AA-47FA-9D88-15CD765F7F68Q63413179-13DA8BA0-E28D-4483-81FA-8E16CB791287Q92292664-75A3C7C5-430F-4485-B553-5749BB268301
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rossano Lattanzio
@ast
Rossano Lattanzio
@en
Rossano Lattanzio
@es
Rossano Lattanzio
@nl
Rossano Lattanzio
@sl
type
label
Rossano Lattanzio
@ast
Rossano Lattanzio
@en
Rossano Lattanzio
@es
Rossano Lattanzio
@nl
Rossano Lattanzio
@sl
prefLabel
Rossano Lattanzio
@ast
Rossano Lattanzio
@en
Rossano Lattanzio
@es
Rossano Lattanzio
@nl
Rossano Lattanzio
@sl
P106
P1153
23100142500
P21
P31
P496
0000-0001-9803-4476